Tamoxifen Suppresses Histologic Progression to Atypia and DCIS in MCFIOAT Xenografts, a Model of Early Human Breast Cancer

Author： Visscher D.W.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.65, Iss.1, 2001-01, pp. : 41-47

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proteomic profiling of lipid rafts in a human breast cancer model of tumorigenic progression

By Caruso Joseph  

Clinical and Experimental Metastasis, Vol. 28, Iss. 6, 2011-08 ,pp. : 529-540

Springer Publishing Company

Access to resources Recommend Favorite

The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts

By Behrens Diana   Lykkesfeldt Anne   Fichtner Iduna  

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 135-144

Springer Publishing Company

Access to resources Recommend Favorite

Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression

By Cameron D.A.  

Breast Cancer Research and Treatment, Vol. 45, Iss. 2, 1997-09 ,pp. : 99-107

Springer Publishing Company

Access to resources Recommend Favorite

Dietary fat and breast cancer metastasis by human tumor xenografts

By Rose D.P.   Connolly J.M.  

Breast Cancer Research and Treatment, Vol. 46, Iss. 2-3, 1997-11 ,pp. : 225-237

Springer Publishing Company

Access to resources Recommend Favorite

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer

By Migliaccio Ilenia  

Breast Cancer Research and Treatment, Vol. 123, Iss. 3, 2010-10 ,pp. : 651-660

Springer Publishing Company

Access to resources Recommend Favorite